WOLFGANG WINKELMAYER to Cost-Benefit Analysis
This is a "connection" page, showing publications WOLFGANG WINKELMAYER has written about Cost-Benefit Analysis.
Connection Strength
0.302
-
Commentary on 'The DOPPS practice monitor for U.S. dialysis care: update on trends in anemia management 2 years into the bundle': iron(y) abounds 2 years later. Am J Kidney Dis. 2013 Dec; 62(6):1217-20.
Score: 0.094
-
The challenges of cost-effectiveness analyses for the clinician. Am J Kidney Dis. 2010 Dec; 56(6):1023-5.
Score: 0.076
-
Comparing the costs, risks, and benefits of competing strategies for the primary prevention of venous thromboembolism. Circulation. 2004 Dec 14; 110(24 Suppl 1):IV25-32.
Score: 0.050
-
Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making. 2002 Sep-Oct; 22(5):417-30.
Score: 0.043
-
Strategies for the management of suspected heparin-induced thrombocytopenia: a cost-effectiveness analysis. Pharmacoeconomics. 2007; 25(11):949-61.
Score: 0.014
-
Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure. Circulation. 2005 Dec 13; 112(24):3745-53.
Score: 0.013
-
The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int. 2003 Jul; 64(1):295-304.
Score: 0.011